ProMetic Enters Into Strategic Alliance with GENERIUM Pharmaceuticals

LAVAL, QUEBEC--(Marketwired - Dec. 22, 2014) - ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF) -

• GENERIUM granted exclusive rights to ProMetic's Plasma Protein Purification System ("PPPS™) derived biopharmaceuticals for Russia and Commonwealth of Independent States ("CIS")

• US $17 million license and milestone fees, of which US $6 million is payable upfront

• GENERIUM to pay ProMetic mid-single digit royalties on sales of biopharmaceuticals in Russia and CIS

• GENERIUM to build and operate a PPPS™ based plasma purification facility to process up to 600,000 liters of plasma annually, in Russia, to manufacture therapeutics for the Russian and CIS markets

• GENERIUM to fund and conduct all required clinical trials in Russia

• GENERIUM and ProMetic create global partnership for the co-development and commercialization of two coagulation factors

ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF), ("ProMetic" or the "Corporation") announced today that it has entered into definitive agreements with GENERIUM Pharmaceuticals ("GENERIUM") for several plasma-derived biopharmaceuticals to be manufactured and commercialized in Russia and CIS, as well as for the co-development and global commercialization of two plasma-derived coagulating factors.

The strategic alliance includes the granting of manufacturing rights by ProMetic to GENERIUM for several plasma-derived biopharmaceuticals using ProMetic's proprietary PPPS™ technology. In addition, ProMetic will provide training and technical support to manufacture said plasma-derived biopharmaceuticals in a facility to be built and operated by GENERIUM, in Russia. The design of the GENERIUM plasma purification facility will be based on ProMetic's own Laval facility and will have a plasma processing capacity of up to 600,000 litres per year. Construction of said facility has already commenced and is expected to be completed by 2017. GENERIUM will fully fund the construction and operating costs of its new cGMP PPPS™ facility.